Ryeqo

Ryeqo is a once-daily oral combination of relugolix 40 mg (a gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces ovarian estradiol production, a hormone known to stimulate the growth of uterine fibroids), estradiol 1.0 mg, and norethisterone acetate 0.5 mg) indicated in Europe for the treatment of uterine fibroids with mild to moderate symptoms.